PepKon Highlights Breakthrough Peptide Therapeutics at NETVA 2024 in Boston

PepKon is proud to have participated in the NETVA 2024 Immersion Week in Boston, organized by the Consulate General of France in Boston and Business France Healthcare - North America. This prestigious event allowed us to connect with Boston’s dynamic biotech ecosystem and highlight our pioneering work in peptide-based oncology treatments.

During the week, PepKon’s CEO, Jonathan Levy, shared insights into our next-generation peptide therapeutics at an exciting pitching session, alongside other innovative startups. Discussions centered around drug discovery, computational modeling, and targeted cancer treatments. Additionally, we engaged with InnoVenture Labs and visited Ginkgo Bioworks, gaining valuable insights into advanced biotech platforms.

As a company focused on peptide therapeutics, PepKon remains dedicated to advancing peptide discovery and oncology engineering. The connections made at NETVA 2024 have set the stage for exciting new collaborations as we continue our mission to develop groundbreaking cancer therapies.

We’re also pleased to share that Jonathan Levy was featured in an interview at the 8th Boston Paris Biotechnology Summit™ on May 15, 2024, at the Cambridge Innovation Center (CIC), Cambridge, MA. In the interview, Jonathan discussed PepKon’s innovative peptide drug candidate, PKT16, which has shown promising activity and low toxicity in preclinical studies. We invite you to listen to it in the following link: https://spreadloveio.com/podcast/hands-on-positive-impact-jonathan-levy/
‍

Thank you to everyone involved in making NETVA 2024 a success. PepKon is excited to continue advancing peptide-based cancer therapies and leading innovation in the biotech industry.